Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acetazolamide

FDA-approved product (tablet, oral), marketed as Acetazolamide, Diamox, Acetazolamide Sodium.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acetazolamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Altitude sickness
  • Angle-closure glaucoma
  • Congestive heart failure
  • Edema
  • Epilepsy
  • Glaucoma
  • Heart failure
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis85.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 6 of 6 lab records
Open Acetazolamide in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acetazolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial

    NCT04907123 · start 2021-10

    Registered record
    Registry ID
    NCT04907123
    Conditions
    Heart Failure
    Interventions
    Intensive sodiuria-guided diuretic treatment; Standard diuretic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10
    Completion
    2025-01
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionIntensive sodiuria-guided diuretic treatment; Standard diuretic treatment
    PhasePhase 3
    Registry statusUnknown

  • Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD

    NCT04913389 · start 2021-06-01

    Registered record
    Registry ID
    NCT04913389
    Conditions
    Chronic Obstructive Pulmonary Disease; Altitude Sickness; Altitude Hypoxia
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2023-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease; Altitude Sickness; Altitude Hypoxia
    InterventionAcetazolamide; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC

    NCT04611373 · start 2020-05-01

    Registered record
    Registry ID
    NCT04611373
    Conditions
    HCC
    Interventions
    Acetazolamide Levamisole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-05-01
    Completion
    2021-05-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCC
    InterventionAcetazolamide Levamisole
    PhasePhase 3
    Registry statusUnknown

  • Treatment of Chronic Mountain Sickness

    NCT04251364 · start 2020-02-15

    Registered record
    Registry ID
    NCT04251364
    Conditions
    Hypoxia, Altitude
    Interventions
    Acetazolamide; Atorvastatin; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-02-15
    Completion
    2021-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypoxia, Altitude
    InterventionAcetazolamide; Atorvastatin; Placebo oral tablet
    PhaseNot applicable
    Registry statusCompleted

  • Acetazolamide in Patients With Acute Heart Failure

    NCT03720288 · start 2018-10-01

    Registered record
    Registry ID
    NCT03720288
    Conditions
    Heart Failure; Acute Heart Failure
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-10-01
    Completion
    2020-10-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Acute Heart Failure
    InterventionAcetazolamide; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

    NCT03715972 · start 2018-07-15

    Registered record
    Registry ID
    NCT03715972
    Conditions
    Thalassemia; Sickle Cell Disease; Healthy Controls
    Interventions
    Hydroxyurea; Acetazolamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-15
    Completion
    2022-12-31
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThalassemia; Sickle Cell Disease; Healthy Controls
    InterventionHydroxyurea; Acetazolamide
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude

    NCT03536507 · start 2018-05-15

    Registered record
    Registry ID
    NCT03536507
    Conditions
    Altitude Hypoxia
    Interventions
    ACETAZOLAMIDE oral capsule; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-15
    Completion
    2018-08-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAltitude Hypoxia
    InterventionACETAZOLAMIDE oral capsule; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted

  • Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude

    NCT03536520 · start 2018-05-15

    Registered record
    Registry ID
    NCT03536520
    Conditions
    Altitude Hypoxia
    Interventions
    ACETAZOLAMIDE oral capsule; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-15
    Completion
    2018-08-02
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAltitude Hypoxia
    InterventionACETAZOLAMIDE oral capsule; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted

  • Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years

    NCT03561675 · start 2018-05-15

    Registered record
    Registry ID
    NCT03561675
    Conditions
    Acute Mountain Sickness
    Interventions
    ACETAZOLAMIDE oral capsule; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-15
    Completion
    2019-08-31
    Enrolment
    349

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Mountain Sickness
    InterventionACETAZOLAMIDE oral capsule; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted

  • Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

    NCT03490916 · start 2018-03-23

    Registered record
    Registry ID
    NCT03490916
    Conditions
    High Altitude Pulmonary Edema
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-03-23
    Completion
    2018-04-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Altitude Pulmonary Edema
    InterventionAcetazolamide; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Rivaroxaban vs. Warfarin in CVT Treatment

    NCT04569279 · start 2017-09-01

    Registered record
    Registry ID
    NCT04569279
    Conditions
    Cerebral Vein Thrombosis
    Interventions
    Rivaroxaban; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2020-03-01
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Vein Thrombosis
    InterventionRivaroxaban; Warfarin
    PhasePhase 3
    Registry statusCompleted

  • Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude

    NCT03165890 · start 2017-05-24

    Registered record
    Registry ID
    NCT03165890
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    ACETAZOLAMIDE oral capsule; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-24
    Completion
    2017-07-24
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionACETAZOLAMIDE oral capsule; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted

  • Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension

    NCT02755259 · start 2017-01-01

    Registered record
    Registry ID
    NCT02755259
    Conditions
    Hypertension, Pulmonary
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-01-01
    Completion
    2019-04-05
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionAcetazolamide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia

    NCT02992938 · start 2016-12

    Registered record
    Registry ID
    NCT02992938
    Conditions
    Hyperalgesia; Opioid-Related Disorders
    Interventions
    Acetazolamide; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-12
    Completion
    2018-09-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperalgesia; Opioid-Related Disorders
    InterventionAcetazolamide; Placebo Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Acetazolamide to Prevent Post Operative CSF Leak

    NCT02902133 · start 2016-09-01

    Registered record
    Registry ID
    NCT02902133
    Conditions
    Cerebrospinal Fluid Leak
    Interventions
    Acetazolamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-09-01
    Completion
    2021-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrospinal Fluid Leak
    InterventionAcetazolamide
    PhasePhase 2
    Registry statusWithdrawn